48 Chapter 2 Table e-1. Baseline demographics, PET, CSF, and MRI values in three-category ATN classification in SCD (continued) Normal AD biomarkers N=385 (55.6%) Non-AD pathologic change N=186 (26.8%) Alzheimer’s continuum N=122 (17.6%) P-value MRI MTA, mean (SD)$ 0.2 (0.3) 0.5 (0.5) 0.5 (0.6) 0.00* GCA, mean (SD) 0.2 (0.4) 0.5 (0.6) 0.4 (0.6) 0.00* PA, mean (SD)$ 0.4 (0.6) 0.6 (0.7) 0.6 (0.6) 0.00* Fazekas, mean (SD) 0.5 (0.6) 0.7 (0.7) 0.9 (0.7) 0.00* Lacunes, n (%)# 12 (3.1%) 11 (5.9%) 6 (4.9%) 0.24 Microbleeds, n (%)# 39 (10.3%) 24 (12.9%) 29 (23.8%) 0.00* Analyses were performed using ANOVA and Fisher’s exact test. *: p-value <0.05. $: average between left and right side. #: values are dichotomized into 0 counts and ≥1 counts. N shown is number of participants with ≥1 counts. MMSE=mini -mental state examination; PET=positron emission tomography; CSF=cerebrospinal fluid; MRI=magnetic resonance imaging; MTA=medial temporal atrophy; GCA=global cortical atrophy; PA=parietal atrophy Normal AD biomarkers: A-T-N-; Non-AD pathologic change: A-T-N+, A-T+N-, A-T+N+; Alzheimer’s continuum: A+T-N-, A+T-N+, A+T+N-, A+T+N
RkJQdWJsaXNoZXIy MjY0ODMw